News
Will Forced Divesture Of Grail Boost Illumina Shareholder Value?
The phrase, “I’m from the government and I’m here to help” has a well-deserved reputation as a terrifying phrase, but for medical researcher Illumina Inc. (NASDAQ: ILMN), which specializes in DNA
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers, inflammatory diseases and sexual dysfunction. It
High-Yield Pfizer Falls Off The COVID Cliff, And Survives
Pfizer (NYSE: PFE) was expected to post a significant decline in revenue and earnings because of the slowing COVID business, and it did. However, the takeaway from the report is that business is
High-Yield Pfizer Falls Off The COVID Cliff, And Survives
Pfizer (NYSE: PFE) was expected to post a significant decline in revenue and earnings because of the slowing COVID business, and it did. However, the takeaway from the report is that business is
Can Butterfly Network Spread its Wings in 2023?
Butterfly Network Inc. (NYSE: BFLY) is a medical imaging solutions company that makes point-of-demand portable ultrasound devices to bring medical imaging to healthcare providers at a deep
Can Butterfly Network Spread its Wings in 2023?
Butterfly Network Inc. (NYSE: BFLY) is a medical imaging solutions company that makes point-of-demand portable ultrasound devices to bring medical imaging to healthcare providers at a deep
Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal
Virios Therapeutics Inc. (NASDAQ: VIRI) is a developmental-stage biotechnology company specializing in novel antiviral therapies for treating fibromyalgia and other abnormal immune
Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal
Virios Therapeutics Inc. (NASDAQ: VIRI) is a developmental-stage biotechnology company specializing in novel antiviral therapies for treating fibromyalgia and other abnormal immune
Why Legend Biotech Stock Is Having Its Best Month Yet
Legend Biotech Corporation (NASDAQ: LEGN) is among the many healthcare names vying for a breakthrough in cancer treatment. Last week, the New Jersey-based company had just that.
On April 19th, a
Why Legend Biotech Stock Is Having Its Best Month Yet
Legend Biotech Corporation (NASDAQ: LEGN) is among the many healthcare names vying for a breakthrough in cancer treatment. Last week, the New Jersey-based company had just that.
On April 19th, a
Why Legend Biotech Stock Is Having Its Best Month Yet
Legend Biotech Corporation (NASDAQ: LEGN) is among the many healthcare names vying for a breakthrough in cancer treatment. Last week, the New Jersey-based company had just that.
On April 19th, a
Medtronic: Reversal In-Play For This High-Yield Stock
The med-tech companies have gotten a lot of attention lately, and Medtronic (NYSE: MDT) is included. The rebound in procedures and healthcare services following the pandemic drives a rebound in
Shockwave Medical Gets 10% Jolt, Leads Medical Gear Makers Higher
The old saying, “I’m from the government, I’m here to help,” is always intended as a punchline, but a Medicare rule changes sure did help shares of Shockwave Medical Inc. (NASDAQ: SWAV).
Shares
Tilray Brands Consolidates Hold: Profits Will Drive Shares Higher
Tilray Brands (NASDAQ: TLRY) reported a mixed quarter and a deal to acquire HEXO that sent the market moving lower. While the news is less than spectacular, there are some takeaways for
Weight Watchers Reshapes Itself with a Game-Changer Acquisition
Weight management food and services provider WW International Inc. (NYSE: WW) stock took a 25% spike as it closed its acquisition of telehealth weight loss platform provider Sequence Inc. WW
Weight Watchers Reshapes Itself with a Game-Changer Acquisition
Weight management food and services provider WW International Inc. (NYSE: WW) stock took a 25% spike as it closed its acquisition of telehealth weight loss platform provider Sequence Inc. WW
MicroVision Releases Video Showing Integration of MAVIN and Perception Software
- Early Evidence of Acquisition Synergies
REDMOND, WA / ACCESSWIRE / February 21, 2023 / MicroVision, Inc. (NASDAQ:MVIS), a leader in MEMS-based solid-state automotive lidar and
MicroVision veröffentlicht Video, das Integration von MAVIN und Perception Software zeigt
- Frühe Anzeichen für Synergien durch Erwerb
Redmond (Washington), ACCESSWIRE, 21. Februar 2023. MicroVision Inc. (NASDAQ: MVIS), ein führender Anbieter von MEMS-basierten
MicroVision und Ibeo bündeln ihre Kräfte
Abschluss der Übernahme ermöglicht raschere Lösungen für Erstausrüster der Automobilindustrie und Ausweitung des Multi-Market-Vertriebs
- Die Übernahme schafft eine Verbindung
MicroVision and Ibeo Join Forces
Completion of the Acquisition Accelerates Solutions for Automotive OEM and Expands Multi-Market Sales
- Acquisition brings together MicroVision's best-in-class MAVIN™ hardware and
Vertex erhält zum sechsten Mal in Folge die HDI-Zertifizierung und ist führend im Bereich des Kundensupports für Steuertechnologie
Die HDI Support Center Certification ist das einzige offene Branchenstandardprogramm zur Zertifizierung der Qualität von Support-Centern
KING OF PRUSSIA, Pennsylvania, Oct. 02, 2024 (GLOBE
Vertex erhält zum sechsten Mal in Folge die HDI-Zertifizierung und ist führend im Bereich des Kundensupports für Steuertechnologie
Die HDI Support Center Certification ist das einzige offene Branchenstandardprogramm zur Zertifizierung der Qualität von Support-Centern
KING OF PRUSSIA, Pennsylvania, Oct. 02, 2024 (GLOBE
Vertex erhält zum sechsten Mal in Folge die HDI-Zertifizierung und ist führend im Bereich des Kundensupports für Steuertechnologie
Die HDI Support Center Certification ist das einzige offene Branchenstandardprogramm zur Zertifizierung der Qualität von Support-Centern
KING OF PRUSSIA, Pennsylvania, Oct. 02, 2024 (GLOBE
Kombination aus TALVEY®▼ (talquetamab) und DARZALEX® (daratumumab) in subkutaner (s. c.) Formulierung zeigt tiefgreifendes und dauerhaftes Ansprechen bei Patienten mit rezidiviertem oder refraktärem Multiplem Myelom
Aktuelle Daten zeigen 100 Prozent Gesamtansprechrate, wobei 56 Prozent der Patienten bei wöchentlicher Verabreichung ein komplettes Ansprechen oder besser erreichten, was die Kombinierbarkeit des
BioNTech stellt auf dem ersten „AI Day” ihre Fähigkeiten im Bereich Künstliche Intelligenz und deren Anwendung in der Forschung und Entwicklung vor
- BioNTech stellt vor, wie unternehmenseigene Fähigkeiten im Bereich Künstliche Intelligenz (artificial intelligence, „AI“) strategisch für die gesamte Immuntherapie-Pipeline angewendet und skaliert